-
Dr. Zhixiang Shen: Ten Years of Transformative Ideas in Hematological Oncology – From Treatment to Management
Conference Highlights: A Wealth of Cutting-edge Developments Dr. Zhixiang Shen: This CSCO Hematology Academic Conference comprehensively presented the latest domestic and international advances in hematological oncology over the past few…
-
Dr. Jing Sun: SYK Inhibitors Set Sail at EHA – Solepinib’s Dual Mechanism Offers New Hope for ITP Treatment
The annual meeting of the European Hematology Association (EHA) is an international conference in the field of hematology, bringing together numerous experts and scholars from around the world to share and delve into innovative ideas and research progress, promoting continuous development in the field of hematology. This year, the research achievements of spleen tyrosine kinase…
-
New Staging of Hepatocellular Carcinoma Using Radiomics Published in eClinical Medicine by Liver Disease Center of Nanfang Hospital
Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths worldwide. Early detection, diagnosis, and intervention can significantly reduce mortality rates. HCC development is driven by a series of complex processes, often starting from hepatitis and cirrhosis. During this progression, subtle changes in cellular gene expression, major shifts in molecular signaling pathways, and significant…
-
Hepatology | Long-term Prognosis and HCC Risk Stratification in Compensated Advanced Chronic Liver Disease Post-HCV Clearance
Chronic hepatitis C virus (HCV) infection is a major cause of cirrhosis and hepatocellular carcinoma (HCC). In recent years, the treatment of HCV infection has undergone revolutionary changes, transforming chronic HCV infection into a curable disease. Although direct-acting antiviral (DAA) therapy can effectively clear HCV, improve liver fibrosis, and reduce the risk of HCC, certain…
-
BOC/BOA 2024 | Professor Tiejun Gong: Interpretation of Three Major Studies in Hematologic Oncology
From July 5th to 7th, the highly anticipated 2024 Annual Progress Seminar in Clinical Oncology in China (BOC) and Best of ASCO 2024 China were grandly held in Guangzhou. Based on the actual situation of cancer incidence in China, the conference specially invited authoritative experts in the field of oncology and carefully selected outstanding papers…
-
BOC/BOA 2024 | Professor Jun Ma: Showcasing Oncology Frontiers and Uniting the Anti-Cancer Front for an Innovative Future
From July 5th to 7th, 2024, the Annual Progress Seminar in Clinical Oncology in China (BOC) and Best of ASCO® 2024 China (BOC/BOA) were grandly held in Guangzhou. In the wake of ASCO’s profound impact, BOC/BOA gathered cutting-edge advancements from home and abroad, showcasing China’s innovative capabilities. With a special focus on hematologic malignancies and…
-
ASCO Hot Review丨Dr. Shanshan Wang: Multiple Prostate Cancer Studies Announced, Further Improving Patient Survival and Quality of Life
Prostate cancer incidence rates in China are currently surging, with high mortality rates and a significant disease burden. Various studies have actively explored ways to improve patients’ quality of life, and evidence for the combination of PARP inhibitors with NHA and immunotherapy has brought new options and hope for prostate cancer treatment. This year’s ASCO…
-
EHA International Perspective | Dr. Consuelo Bertossi: Key Findings on TP53 Mutations in Chronic Lymphocytic Leukemia (CLL)
TP53 mutations not only profoundly affect the progression trajectory of chronic lymphocytic leukemia (CLL), but are also directly associated with poor prognosis, becoming an important factor that cannot be ignored when assessing disease severity and formulating personalized treatment strategies. At the highly anticipated 29th Annual Congress of the European Hematology Association (EHA 2024), Dr. Consuelo…
Connecting Medical Expertise through Media